News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ocutherix Developing University of Colorado Next-Generation Glaucoma Treatment


3/19/2014 11:39:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AURORA, Colo., March 19, 2014 – OcuTherix, Inc. and the University of Colorado (CU) have completed an exclusive license that will allow the company to continue developing a new non-invasive procedure for the treatment of glaucoma that uses patent-pending technology developed at CU.

Glaucoma is a leading cause of worldwide blindness, and is treated by lowering the fluid pressure inside the eye (intraocular pressure). Topical eye-drop medications are often used to lower eye pressure, but because these medications can cause discomfort, patients often fail to take them correctly and consistently. Laser and surgical procedures are also used to reduce eye pressure; however, these techniques are fraught with complications and do not consistently reduce eye pressure in the long term.

A research team led by Malik Kahook, MD, Slater Family Endowed Chair in Ophthalmology at the CU School of Medicine, has developed a compact, non-invasive device that uses carefully calibrated external sonic oscillation to stimulate drainage of the eye’s fluid, reducing eye pressure. This innovative procedure, called Deep Wave Trabeculoplasty (DWT), is intended to be an efficient, safe and effective in-office treatment. Studies have shown that DWT does not cause tissue damage and lowers eye pressure consistently. An ongoing clinical study is intended to demonstrate that DWT has long-lasting benefits and can be repeated when needed. “The initial DWT study in humans revealed consistent eye pressure lowering without adverse events,” said Kahook. “Our team believes that DWT will play a significant role in the treatment of glaucoma in the United States and across the globe.”

“Gradual vision loss is devastating, and I am proud to be working with outstanding partners to develop DWT as we strive to save vision in people with glaucoma,” added OcuTherix CEO Robert Atkinson. “I strongly believe that DWT represents a new age in glaucoma treatment.”

“We believe this device represents a completely novel approach to the treatment of glaucoma, and the University is excited to work with a company that will help Dr. Kahook develop such a pioneering technique,” said David Poticha of CU’s Technology Transfer Office.

About OcuTherix, Inc.:

OcuTherix, a spin-out company of medical device incubator Prospex Medical, Inc., is dedicated to medical device innovation to save vision in people with glaucoma. CAUTION: Deep Wave Trabeculoplasty (DWT) is an investigational device and is not approved for sale. www.ocutherix.com

About the Technology Transfer Office and the University of Colorado:

The CU Technology Transfer Office pursues, protects, packages, and licenses to business the intellectual property generated from research at CU. The TTO provides assistance to faculty, staff, and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU, visit www.cu.edu/techtransfer.

The University of Colorado is a premier public research university with four campuses: the University of Colorado Boulder, the University of Colorado Colorado Springs, the University of Colorado Denver and the University of Colorado Anschutz Medical Campus. With nearly 58,000 students, over 4,700 full-time instructional faculty members and an additional 1,200 research faculty members across the four campuses, CU is the largest institution of higher education in the state of Colorado. Academic prestige is marked by the university’s five Nobel laureates, eight MacArthur “genius” Fellows, 18 alumni astronauts and 19 Rhodes Scholars. For more information about the entire CU system, and to access campus resources, go to www.cu.edu.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES